Karyopharm presents xpovio® (selinexor) data in multiple myeloma and diffuse large-b-cell lymphoma at the american society of hematology 2020 annual meeting

Newton, mass., dec. 7, 2020 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that over twenty presentations related to xpovio® (selinexor), the company's first-in-class, oral selective...
KPTI Ratings Summary
KPTI Quant Ranking